/VACC

VACC Stock - Vaccitech plc

Q: What is the analyst price target for VACC?

Analyst price target information is not currently available for VACC.

Q: What is VACC's market cap?

Market capitalization information is not currently available for VACC.

Healthcare|Biotechnology|NASDAQ

$5.00+11.36%

+$0.51 (+11.36%) • Nov 6

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $5.50

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for VACC

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2019

FY2020

FY2021

FY2022

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta-0.27

52W High$5.10

52W Low$1.64

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2022	FY2021	FY2020	FY2019
Revenue	$14.97M	$44.70M	$268,000	$4.82M	$6.85M
Gross Profit	N/A	$2.35M	$-20,103,000	$-9,566,743	$-22,997,305
Gross Margin	0.0%	5.3%	-7501.1%	-198.5%	-336.0%
Operating Income	$1.18M	$-3,454,000	$-45,221,000	$-20,046,948	$-22,688,800
Net Income	$-61,074,000	$5.34M	$-51,112,000	$-17,933,558	$-20,729,592
Net Margin	-408.0%	11.9%	-19071.6%	-372.0%	-302.8%
EPS	$-1.55	$0.14	$-1.97	$-2.27	$-883.28

Company Overview

Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.

Visit Website

Earnings History & Surprises

VACC

Beat Rate

82%

Last 11 quarters

Avg Surprise

+61.2%

EPS vs Estimate

Beats / Misses

9/2

Last 12 quarters

Latest EPS

$0.22

Q4 2023

EPS Surprise History

Q1 22

+25.5%

$-0.38vs$-0.51

Q2 22

+122.6%

$0.07vs$-0.31

Q3 22

+228.1%

$0.41vs$-0.32

Q4 22

+166.7%

$0.22vs$-0.33

Q1 23

-111.5%

$-0.55vs$-0.26

Q2 23

+17.2%

$-0.48vs$-0.58

Q3 23

-5.1%

$-0.62vs$-0.59

Q4 23

+135.5%

$0.22vs$-0.62

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q4 2023	Nov 9, 2023	$-0.62	$0.22	+135.5%	✓ BEAT
Q3 2023	Aug 10, 2023	$-0.59	$-0.62	-5.1%	✗ MISS
Q2 2023	May 12, 2023	$-0.58	$-0.48	+17.2%	✓ BEAT
Q1 2023	Mar 24, 2023	$-0.26	$-0.55	-111.5%	✗ MISS
Q4 2022	Nov 10, 2022	$-0.33	$0.22	+166.7%	✓ BEAT
Q3 2022	Aug 9, 2022	$-0.32	$0.41	+228.1%	✓ BEAT
Q2 2022	May 11, 2022	$-0.31	$0.07	+122.6%	✓ BEAT
Q1 2022	Mar 25, 2022	$-0.51	$-0.38	+25.5%	✓ BEAT
Q4 2021	Nov 12, 2021	$-0.45	$-0.13	+71.1%	✓ BEAT
Q3 2021	Aug 12, 2021	$-0.74	$-0.64	+13.5%	✓ BEAT
Q2 2021	Jun 14, 2021	$-2.11	$-1.90	+10.0%	✓ BEAT
Q4 2020	Dec 31, 2020	—	$-1.31	—	—
Q3 2020	Sep 30, 2020	—	$0.01	—	—
Q2 2020	Jun 30, 2020	—	$-0.45	—	—
Q1 2020	Mar 31, 2020	—	$-0.49	—	—